Biliary tract cancer (BTC) represents the second most frequently diagnosed primary liver cancer worldwide following hepatocellular carcinoma, and the overall survival of patients with unresectable disease remains poor. In recent years, the advent of immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic landscape of several malignancies with these agents, which have also been explored in advanced BTC, as monotherapy or in combination with other anticancer agents. However, clinical trials evaluating ICIs in BTC have shown conflicting results, and the clinical benefit provided by immunotherapy seems limited to a small subgroup of BTC patients. Thus, the identification of reliable predictors of the response to immunotherapy represents a significant challenge in this setting. This review provides an overview of the available evidence on the biomarkers predictive of the response to ICIs in patients with advanced BTC, especially focusing on programmed death‐ligand 1 (PD‐L1), tumor mutational burden (TMB), microsatellite instability (MSI), and other emerging biomarkers.

Rizzo A., Ricci A.D., Brandi G. (2021). Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. CANCERS, 13(3), 1-11 [10.3390/cancers13030558].

Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer

Ricci A. D.;Brandi G.
2021

Abstract

Biliary tract cancer (BTC) represents the second most frequently diagnosed primary liver cancer worldwide following hepatocellular carcinoma, and the overall survival of patients with unresectable disease remains poor. In recent years, the advent of immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic landscape of several malignancies with these agents, which have also been explored in advanced BTC, as monotherapy or in combination with other anticancer agents. However, clinical trials evaluating ICIs in BTC have shown conflicting results, and the clinical benefit provided by immunotherapy seems limited to a small subgroup of BTC patients. Thus, the identification of reliable predictors of the response to immunotherapy represents a significant challenge in this setting. This review provides an overview of the available evidence on the biomarkers predictive of the response to ICIs in patients with advanced BTC, especially focusing on programmed death‐ligand 1 (PD‐L1), tumor mutational burden (TMB), microsatellite instability (MSI), and other emerging biomarkers.
2021
Rizzo A., Ricci A.D., Brandi G. (2021). Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. CANCERS, 13(3), 1-11 [10.3390/cancers13030558].
Rizzo A.; Ricci A.D.; Brandi G.
File in questo prodotto:
File Dimensione Formato  
pdl1.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 631.92 kB
Formato Adobe PDF
631.92 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/875907
Citazioni
  • ???jsp.display-item.citation.pmc??? 68
  • Scopus 164
  • ???jsp.display-item.citation.isi??? 149
social impact